Compound Overview
Semaglutide is a single GLP-1 (glucagon-like peptide-1) receptor agonist and one of the most extensively studied compounds in metabolic research. As the mechanistic baseline against which dual agonists (Tirzepatide) and triple agonists (Retatrutide) are compared, it holds a foundational place in the GLP-1 research landscape.
Semaglutide is sold strictly as a research compound. It is not approved for human use outside specific FDA-authorized therapeutic contexts, and all research applications must remain within appropriate laboratory frameworks.
Semaglutide selectively activates the GLP-1 receptor, mimicking the endogenous incretin hormone. Research in animal models and clinical trials has explored its effects on insulin secretion, glucagon regulation, gastric emptying, and appetite-signaling pathways.
As research has moved toward multi-receptor compounds, Semaglutide remains an important comparative reference. Studies isolating the contribution of GLP-1 receptor activation alone — without the GIP component of Tirzepatide or the glucagon component of Retatrutide — depend on Semaglutide as the single-pathway control.
This makes it valuable not only as a research subject in its own right but as a methodological anchor for comparative protocol design across the GLP-1 class.
As with all GLP-1 class compounds, purity and identity verification are essential. Look for ≥98% HPLC purity and mass spectrometry confirmation of molecular weight. Plato Peptides carries Semaglutide with COA documentation from independent laboratories.